Cytochrome P450 2C19 Genotyping

CPT: 81225
Updated on 8/12/2019
Print Share

Expected Turnaround Time

5 - 10 days

Related Documents

Specimen Requirements


Whole blood or LabCorp buccal swab kit (Buccal swab collection kit contains instructions for use of a buccal swab, PeopleSoft N° 3177.)


7 mL whole blood or LabCorp buccal swab kit

Minimum Volume

3 mL whole blood or two buccal swabs


Lavender-top (EDTA) tube, yellow-top (ACD) tube, or LabCorp buccal swab kit

Storage Instructions

Maintain specimen at room temperature or refrigerate at 4°C.

Causes for Rejection

Frozen specimen; hemolysis; quantity not sufficient for analysis; improper container; one buccal swab; wet buccal swab

Test Details


This testing can assist with customizing drug therapy by providing metabolic activity information that may explain patient drug responses relevant to CYP2C19 genetic variability. The cytochrome P450 (CYP450) enzymes metabolize many drugs. Individual genetic differences of cytochrome P450 activity can result in the total absence of metabolism to ultrafast metabolism of certain drugs.


This assay does not detect other variants in the CYP2C19 gene that may affect metabolic activity.

The metabolism of drugs is also influenced by ethnicity, diet, and other medications. All factors should be considered prior to initiating new therapy. This testing does not rule out the possibility of variant alleles in other drug metabolism pathways.


DNA analysis of the Cytochrome P450 2C19 gene (OMIM 124020, 10q24.1-10q24.3) is performed using primer extension chemistry. Multiplex PCR amplifies DNA fragments containing the variants below. Primer extension then generates a biotin-labeled product to perform flow-sorted detection of both normal and variant sequences. Molecular-based testing is highly accurate, but as in any laboratory test, rare diagnostic errors may occur.

Alleles detected: *1,*2,*3,*17

*1 represents detection of the normal sequence for the variant sites tested.

Additional Information

Common prescription medications that may be impacted by CYP2C19 gene variants are listed below. The following list is intended as a guide and is not inclusive of all clinically relevant drugs.

Platelet Aggregation Inhibitor: Clopidogrel

Poor metabolizers (PM) and intermediate metabolizers (IM) are at risk for recurrence of cardiovascular atherosclerotic disease. Alternative antiplatelet agents are recommended for PM patients and may be considered for IM patients, if not clinically contraindicated. Ultrarapid metabolizers (UM) may have an enhanced response to clopidogrel, and may be at an increased risk of bleeding. Standard dosing may be considered for UM patients. Coadministration of clopidogrel alongside CYP2C19 inhibitors such as omeprazole, esomeprazole, lansoprazole, felbamate, fluvoxamine, oral contraceptives, and voriconazole can reduce clopidogrel's platelet inhibition.

Tricyclic antidepressants (Tca): Amitriptyline, nortriptyline

Important Interactions: Studies suggest that PMs may benefit from a lower starting dose.

Selective serotonin reuptake inhibitor (Ssri): Citalopram, sertraline

Important Interactions: Mean clearance rates may be decreased in PMs as compared with EMs. Studies suggest that PMs may be at risk for SSRI related cardiotoxicity.

Proton pump inhibitors: Omeprazole

Important Interactions: Data suggests improved cure rates for EM and PM with double or triple therapy.

Antiepileptics: Diazepam, phenytoin

Important Interactions: Diazepam half-life is significantly prolonged in 2C19 PM and may cause prolonged sedation, particularly if administered with inhibitors of 2C19.


Hicks JK, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013 May;93(5):402-408.21716271
Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-134.25974703
LabCorp Pharmacogenetic Testing flyer (L14582). Available upon request.
Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 Update. Clin Pharmacol Ther. 2013;94(3):317-323.23698643
Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010 Feb 2;121(4):512-518.20083681
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363-75.19106083


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
511675 Cytochrome P450 2C19 504204 2C19 Genotype: 57132-3
511675 Cytochrome P450 2C19 504205 2C19 Metabolic Activity: 79714-2
511675 Cytochrome P450 2C19 504632 Director Review: 69426-5
511675 Cytochrome P450 2C19 504433 Interpretation: 72879-0
511675 Cytochrome P450 2C19 504434 CYP2C19 Information: 49549-9
511675 Cytochrome P450 2C19 000000 MGRM Informed Consent Review N/A

For Providers

Please login to order a test.


© 2019  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at